Alexander Mayweg – Startup Investor Profile

Alexander Mayweg, Ph.D., is a Managing Director at Versant Ventures and the head of Ridgeline Therapeutics, the Basel-based Discovery Engine of Versant. He excels in drug discovery and medicinal chemistry, drawing on his experience at Roche Pharma Research. Mayweg’s investment focus areas at Versant Ventures are in early biotech investment and company creation, with a keen interest in sourcing innovative opportunities globally within the healthcare industry. His geographical preference spans Europe, the U.S., and Asia. Since 2016, Alexander has been involved in launching and investing in companies like Black Diamond, Monte Rosa, Bright Peak, Enterprise, T-knife, and Matterhorn. With a Ph.D. in organic chemistry from Oxford University, Alexander brings deep operating capabilities and a strong track record to his role, reflecting his commitment to fostering partnerships and collaborations within the industry.

Location:

Country: Switzerland

Investment Regions: EU, SEA

Investment Stages: pre-seed, seed

Website: https://www.versantventures.com/team/alex-mayweg

AI Reasoning: I found recent activity indicating Alexander Mayweg was involved with Versant-backed company activity within the past 6 months. Specifically, Bright Peak Therapeutics and Black Diamond-related spinouts show continued board and founding involvement; Versant’s site and portfolio pages indicate ongoing investments and company launches through 2024-2025. The most recent evidence places his last known investment/launch within the 6-month window, so classify as very-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.